Table 3 Outcomes
Outcome | Total (n = 156) | Carbapenem therapy (n = 69) | Non carbapenem therapy (n = 87) | OR | β | 95% CI (OR or β) | p-value |
|---|---|---|---|---|---|---|---|
Primary outcome | |||||||
D-30 mortality, n (%) | 16 (10) | 10 (15) | 6 (7) | 0.5 | 0.19;1.80 | 0.14 | |
Secondary outcomes | |||||||
ICU mortality, n (%) | 20 (13) | 11 (16) | 9 (10) | 0.7 | 0.26;1.88 | 0.42 | |
Day-90 mortality, n (%) | 25 (16) | 12 (17) | 13 (15) | 0.9 | 0.38;2.30 | 0.90 | |
ICU length of stay (days), median ± IQR | 5 [3;8] | 5 [4;10] | 4 [3;7.5] | −0.26 | −4.52;4.44 | 0.90 | |
Hospital length of stay (days), median ± IQR | 15 [10;27.5] | 15 [10;27] | 15 [9;27] | −0.85 | −7.75;6.85 | 0.82 | |
Mechanical ventilation, n (%) | 45 (30) | 24 (35) | 21 (24) | 0.5 | 0.28;1.08 | 0.09 | |
Renal replacement therapy, n (%) | 25 (16) | 14 (20) | 11 (13) | 0.5 | 0.22;1.21 | 0.10 | |
Total duration norepinephrine (hours), median ± IQR | 48 [36–72] | 48 [36–72] | 48 [36–72] | 5.4 | −11.34;22.21 | 0.52 | |
Maximal dose norepinephrine (gamma/kg/min), median ± IQR | 0.4 [0.2–0.7] | 0.5 [0.3–0.7] | 0.4 [0.3–0.6] | −0.17 | −0.39;0.03 | 0.09 | |